ANT-GROUP-DIGITAL
3.11.2022 10:19:44 CET | Business Wire | Press release
Ant Group Digital Technologies, a digital technology provider under Ant Group, today unveiled its blockchain storage engine “LETUS” (Log-structured Efficient Trusted Universal Storage) at the Apsara Conference 2022 in Hangzhou.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005680/en/
Yan Ying, Technical Director of AntChain, unveiled the LETUS at the Apsara Conference (Photo: Business Wire)
LETUS, which was developed and designed by the AntChain team, will increase the effectiveness and lower the storage costs for blockchain networks.
Blockchain is a distributed peer-to-peer network, with each node storing data such as blocks and states. The LETUS storage engine is deployed at each blockchain node to provide trusted storage support. At the same time, LETUS has the advantages in performance, large scale workloads handling capability, cost, and resource efficiency through Smart Thermo-control Tiering and Boundary Scan Based Batch Pruning.
“As more and more digital assets are stored on the blockchain, storage capacity and efficiency has increasing impact on the overall performance of blockchain platforms, including transaction speeds and operational costs,” said Yan Ying, Technical Director of AntChain. “Compared to current mainstream industry solutions, LETUS can improve storage throughput by 15 times, reduce latency by 90%, and save disk bandwidth and space usage by 95% and 60%, respectively."
LETUS has already been deployed and running in Topnod, a digital collectibles platform powered by AntChain. It has helped the platform greatly improve performance and reduce storage costs by about 75%.
“For the many industries undergoing digital transformations, mutual trust between companies and customers is increasingly important. At Ant, we have been investing in research and development for blockchain and other digital technologies that help to increase both trust and security,” said Geoff Jiang, President of Digital Technology Business Group at Ant Group. “We remain focused on the technological breakthroughs that create a trusted digital network to improve industrial collaboration and allow us to use our innovative products and services to better serve the real economy.”
During the conference, Ant Group Digital Technologies also released the:
- 4.0 version of mPaaS, its one-stop mobile development solution;
- 2.0 version of its Morse MPC (Multi-party Computation) platform;
- 4.0 version of SOFAStack, its cloud-native PaaS platform;
- 4.0 version of OceanBase Community Edition, its distributed database; and
- other security products.
In the past two years, Ant Group Digital Technologies has also released a number of blockchain-related products and solutions, including:
- AntChain Station, the all-in-one workstation;
- Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology;
- Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment;
- FAIR, the data privacy collaboration platform; and
- T1 security chip, its self-developed blockchain-powered security chip.
Many of these cutting-edge solutions have been successfully deployed by Chery Automobile, Zhejiang Huatie Emergency Equipment Science and Technology and other industry partners.
Ant Group Digital Technologies
Ant Group Digital Technologies continues to promote the development and application of digital technology, introducing leading products like AntChain, OceanBase, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support the small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom